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www.embomolmed.org EMBOInsulin-like growth factor 2 (IGF2) and the transformation related protein 53
(Trp53) are potent regulators of cell growth and metabolism in development and
cancer. In vitro evidence suggests several mechanistic pathway interactions.
Here, we tested whether loss of function of p53 leads to IGF2 ligand pathway
dependency in vivo. Developmental lethality occurred in p53 homozygote null
mice that lacked the paternal expressed allele of imprinted Igf2. Further lethality
due to post-natal lung haemorrhage occurred in female progeny with Igf2
paternal null allele only if derived from double heterozygote null fathers, and
was associated with a specific gene expression signature. Conditional deletion of
Igf2fl/fl attenuated the rapid tumour onset promoted by homozygous deletion of
p53fl/fl. Accelerated carcinoma and sarcoma tumour formation in p53þ/ females
with bi-allelic Igf2 expression was associated with reductions in p53 loss of
heterozygosity and apoptosis. Igf2 genetic dependency of the p53 null phenotype
during development and tumour formation suggests that targeting the IGF2
pathway may be useful in the prevention and treatment of human tumours with a
disrupted Trp53 pathway.INTRODUCTION
The tumour suppressor gene p53, expressed throughout
development and adult life, is frequently disrupted in human
cancers (Olivier et al, 2002). DNA damage, oncogene activation,
telomere erosion, nucleotide depletion and hypoxia, can
activate p53 cellular responses including cell-cycle arrest,
apoptosis, senescence and DNA repair (Menendez et al, 2009;
Riley et al, 2008; Vousden & Prives, 2009). Degradation of









Mol Med 4, 705–718the human double minute 2 (MDM2/4) ubiquitin E3 ligase
which is itself a transcriptional target of Trp53 (Marine &
Lozano, 2010). Individuals with Li-Fraumeni syndrome (LFS)
develop early onset cancers, and in 30–50% of cases, the
tumours are attributed to germ-line heterozygote mutation of
p53 with associated loss of heterozygosity (LOH) of the wild-
type (WT) allele (Malkin, 2011; Srivastava et al, 1990).
Modifiers alter the age of tumour onset in LFS. A single
nucleotide polymorphism (SNP) of the MDM2 (SNP 309) gene
promoter regulates the relative expression level of this
negative regulator of p53 (Bond et al, 2004). SNP 309 associated
gain of function of MDM2/4 expression renders p53 functionally
null, and reduces the age of tumour onset in LFS by 7–15 years
(Bond et al, 2004). A modifier in p53 itself (Trp53 codon 72) also
reduces the age of tumour onset, but is more modest at 2–3 years
(Fang et al, 2010). Screening of LFS patients for early onset
tumours significantly impacts overall survival, such that
identification of pathway modifiers of lethal tumour phenotypes
have implications for both screening and prevention therapies
(Villani et al, 2011).
Mice with homozygous disruption of p53 (p53/) are viable
except for an exencephalic phenotype in females (Armstrong
et al, 1995; Clarke et al, 1993; Donehower et al, 1992). 2012 EMBO Molecular Medicine 705
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706Homozygote animals die within 6 months, due mainly to thymic
lymphoma. p53 heterozygosity markedly reduces lymphoma,
sarcoma and epithelial tumour latency and mirrors the
phenotype of LFS (Donehower et al, 1992; Jacks et al, 1994).
Increased p53 expression and conditional restoration of p53
function resulted in reduced tumour frequency, senescence and
tumour regression (Martins et al, 2006; Ventura et al, 2007; Xue
et al, 2007). p53 is frequently mutated at specific ‘hotspot’ bases
in tumours. Mutations can lead to gain of function, as p53R172H/þ
and p53R270H/þ can increase in carcinomas and osteosarcoma in
the former, and carcinoma metastasis in the latter (Lang et al,
2004; Olive et al, 2004). Modelling of Mdm2 SNP alleles (SNP
309G of MDM2) in the mouse has validated effects on tumour
latency (Post et al, 2010). Stabilization of mutant p53 is also
required in tumours, and is frequently associated with
aggressive tumour phenotypes that can be induced by similar
modifiers to those that regulate WT p53 (Suh et al, 2011). Thus
modelling potential pathway modifiers of p53 loss and gain of
function are important intermediary steps in the validation of
clinically important pathway targets for tumour treatment.
Evidence in vitro suggests convergence between IGF-PI3K-
AKT-mTOR and ARF-MDM2-p53 pathways, mainly through
promotion of IGF-PI3K-AKT-mTOR pathway activation follow-
ing loss of p53 function. Interactions include; phosphorylation
of MDM2 by Akt (Feng et al, 2004; Mayo & Donner, 2001),
transcription of the ligand IGF2 (Lee et al, 2000; Zhang et al,
1996, 1998) and regulation of the insulin-like growth factor
receptor 1 (IGF1R; Ungewitter & Scrable, 2010; Werner et al,
1996). Insulin-like growth factor binding proteins (IGFBP-2, -3
and -7) are negative regulators of IGF bio-availability and are
also p53 target genes (Buckbinder et al, 1995; Grimberg et al,
2006; Suzuki et al, 2010). Function of p53 may be mediated by
Phlda3, a negative regulator of Akt (Brady et al, 2011), and via
activation of PTEN (Stambolic et al, 2001), TSC2, AMP1 (Feng
et al, 2007), sestrins 1 and 2 (Budanov & Karin, 2008) or REDD1
(Ellisen et al, 2002).
IGF2 mRNA over-expression increases ligand supply in
common human cancers mainly due to loss of imprinting
(LOI, bi-allelic expression; Foulstone et al, 2005; Ito et al, 2008).
Binding of insulin-like growth factor 2 (IGF2) to IGF1R and
isoform A of the insulin receptor (IR-A) transmits downstream
signalling via IRS1 and IRS2 to both the PI3K-AKT-mTOR
and RAS-RAF-MEK-ERK pathways (Chalhoub & Baker, 2009;
Ulanet et al, 2010). Supply of IGF2 is also controlled via its
sequestration by the mannose 6-phosphate/insulin-like growth
factor receptor 2 (Igf2r; Foulstone et al, 2005; Ghosh et al, 2003;
Zaccheo et al, 2006). Igf2 expression is imprinted (maternal
allele silenced) in the mouse, leading to paternal allele
expression that is also highly regulated during embryonic and
post-natal development (Baker et al, 1993). Targeted disruption
of the paternal (p) allele of Igf2 (Igf2þm/p) regulates whole
organism growth (60% of the size of WT littermates; Burns &
Hassan, 2001; DeChiara et al, 1990, 1991). Maternal (m)
disruption of the imprinting control region (ICR) and the H19
gene (H19D13kb/þp) subsequently referred to as H19m/þp,
results in bi-allelic Igf2 expression and an overgrowth
phenotype of 128% of the size of WT littermates (Leighton 2012 EMBO Molecular Medicineet al, 1995). Importantly, the H19m/þp growth phenotype was
rescued by Igf2þm/p, suggesting that the predominate growth
effects were mediated by Igf2, rather than as a consequence of
the disruption of either the maternal allele locus, H19 non-
coding RNA or the associated miR-675 (Gabory et al, 2009;
Veronese et al, 2010; Yoshimizu et al, 2008). Igf2 can be
reactivated in mouse tumours by LOI, where it promotes tumour
progression (Christofori et al, 1994, 1995). DNA hypomethyla-
tion also results in increased Igf2 expression and tumour
promotion (Gaudet et al, 2003; Linhart et al, 2007). Here we
provide in vivo evidence of significant Igf2 dependency of the
p53 null phenotype during development and tumour formation.RESULTS
Igf2-dependent developmental lethality of p53 null mice
Mice with varying allelic doses of Igf2 and p53 were combined.
Igf2þm/p are deficient in Igf2 expression because of disruption
of the expressed paternal allele associated with silencing
(imprinting) of the maternal allele. H19m/þp over-express
Igf2 because of disruption of imprinting of the maternal allele
ICR leading to bi-allelic expression (p, paternal allele; m,
maternal allele; þ, intact allele; , disrupted allele). These lines
were first crossed with heterozygote p53þ/ mice. The double
heterozygote (e.g. Igf2þm/p, p53þ/ or H19m/þp, p53þ/)
progeny were subsequently inter-crossed to generate combined
genotypes including double homozygote alleles. As there are
known strain-dependent phenotypic effects in p53 null mice
(Harvey et al, 1993), we utilized both the 129S2/J (129) and
C57BL/6J (B6) genetic backgrounds backcrossed by >20
generations. We were unable to backcross Igf2þm/p onto a
B6 background, and so 129/B6 F2 hybrids were generated (see
Supporting Information Table S1).
The initial observation was that litter sizes from the 129
double heterozygote inter-cross (Igf2þm/p, p53þ/ Igf2þm/p,
p53þ/) appeared significantly smaller, suggesting there was an
overall loss of progeny (Fig 1A). This was only observed when
breeding from double heterozygote mothers (Igf2þm/p, p53þ/,
Supporting Information Fig S1A and B) and appeared indepen-
dent of the parental Igf2 dose (Supporting Information Fig S2).
The majority of implantation sites in double heterozygote
(Igf2þm/p, p53þ/) mothers appeared abnormal (Supporting
Information Fig S1C). Haemorrhage was observed within the
maternal decidua at implantation sites in double heterozygote
(Igf2þm/p, p53þ/) mothers, and was less frequently observed
in either p53þ/ or Igf2þm/p heterozygote mothers (Supporting
Information Fig S1C and D).
At birth, either H19m/þp, Igf2þm/p or p53þ/ alleles
exhibited the expected Mendelian segregation (129, B6
and F1/F2, Supporting Information Tables S2 and S3).
The exception, however, were the results from a 129 double
heterozygote null inter-cross (e.g. Igf2þm/p, p53þ/
Igf2þm/p p53þ/; Table 1). Evaluation of 297 mice from 34
litters led to three further observations.
First, genotypes associated with loss of function of the
paternal expressed Igf2 allele were 60% smaller from birthEMBO Mol Med 4, 705–718 www.embomolmed.org
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Figure 1. Combination of Igf2 and p53 null alleles results in
developmental lethality independent of embryo growth.
A. Mean litter size at P0 was significantly reduced from Igf2þm/p, p53þ/
inter-cross (p<0.0001, n¼ 67 litters) relative to Igf2þm/p mated with
WT (n¼11 litters), p53þ/ mated with WT (n¼ 15 litters) and Igf2þm/p
mated with p53þ/ (n¼ 36 litters; one-way ANOVA, Tukey’s multiple
comparison).
B. Post-natal growth of progeny from a double heterozygote inter-cross (129,
Igf2þm/p, p53þ/). Mean weights of WT and Igf2m/þp mice were sig-
nificantly greater (p<0.0001, one-way ANOVA, Tukey’s multiple com-
parison) than Igf2þm/p and Igf2m/p mice regardless of allelic dosage of
p53.
C. Increased post-natal mortality by p30 in progeny null for both Igf2 and p53
(Igf2þm/p, p53/, 2 of 7 and Igf2m/p, p53/, 5 of 9) relative to WT mice
(1 of 15, p¼0.037, Fisher’s exact test).
Table 1. Abnormal Mendelian segregation of progeny from a Igf2þm/p, p53þ/
Strain WT Igf2þ/ Igf2/ p53þ/ Igf2þ/
p53þ/
129 15 17 7 24 71
(12.94) (25.88) (12.94) (25.88) (51.75)
0.329 3.044 2.725 0.136 7.161
129B6F2 7 22 5 19 33
(7.88) (15.75) (7.88) (15.75) (31.5)
0.097 2.480 1.049 0.671 0.071
Progeny did not segregate according to a normal Mendelian distribution ( p< 0.02,
a normal Mendelian distribution. Observed (upper), expected (middle, in bracket
www.embomolmed.org EMBO Mol Med 4, 705–718(Fig 1B). Second, pre-natal and post-natal lethality occurred
in homozygote null p53 combined with disruption of
the paternal expressed allele of Igf2 (Igf2þm/p, p53/ and
Igf2m/p, p53/ mice). The lethality was observed by birth
(16 of 44 expected), but also continued during the post-natal
period and was associated with no obvious developmental
abnormalities (Fig 1C). Third, there was specific absence of
Igf2þm/p female progeny. Post-natal (P3.5) loss of Igf2þm/p in
both sexes was expected based on steroid responsive delayed
lung development (Table 1; Silva et al, 2006). However, a deficit
specific to females occurred in our case (Fig 2A and Table 2). If
double heterozygote (Igf2þm/p, p53þ/) males were crossed
with either WT or p53þ/ females (Table 2), we again failed to
obtain any live Igf2þm/p females. Thus, combined loss of alleles
for both p53 and Igf2 in the paternal germ-line appeared
incompatible with specific survival of subsequent Igf2þm/p,
p53þ/þ female progeny. In contrast, double heterozygote
(Igf2þm/p, p53þ/) female littermates survived beyond post-
natal day 10, indicating the lethality could be rescued by loss of
an allele of p53. Morphological appearances of embryos
appeared normal between E9.5 and E18.5, even though
Igf2þm/p embryos were smaller (Supporting Information
Fig S3). Following delivery by caesarean section at E19.5,
Igf2þm/p females became increasingly cyanotic (Fig 2B).
Analysis of organ growth revealed that the mean wet weights
of lungs from Igf2þm/p females were significantly reduced










29 18 17 9 207
(25.88) (12.94) (25.88) (12.94) p<0.02
0.377 1.981 3.044 1.198 19.995
12 8 13 7 126
(15.75) (7.88) (15.75) (7.88) p¼NS
0.893 0.002 0.480 0.097 5.841
x2-test). In contrast, progeny from the 129B6F1 Igf2þ/, p53þ/ inter-cross had
s) and x2 (lower).
 2012 EMBO Molecular Medicine 707
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Figure 2. Lethality of female Igf2Rm/p progeny derived from Igf2Rm/p, p53R/ fathers is associated with reduced lung growth.
A. Male (n¼ 115) and female (n¼87) progeny at P10 from the 129 Igf2þm/p, p53þ/ inter-cross did not segregate according to the expected Mendelian
distribution (see Table 1; p< 0.05) and were significantly different to expected numbers estimated from previous litter sizes (total expected numbers:
males¼ 175, females¼ 175 based on mean litter size from earlier 129 breeding, p<0.0001, x2-test). Solid bars, observed numbers, grey unfilled bars,
expected numbers (see also Table 2).
B. Litter of 13 pups delivered by caesarean section at E19.5 from a WT female mated with Igf2þm/p, p53þ/ male. One Igf2þm/p female (white arrow) became
increasingly cyanotic and died 1hr post-delivery. The remaining four Igf2þm/p females (thick black arrows) were also cyanotic compared to their littermates
(thin black arrow points to a representative Igf2þm/p male).
C. Lung weights from E18.5 Igf2þm/p female progeny derived from Igf2þm/p, p53þ/ fathers were significantly lower than those from Igf2þm/p male progeny
(p¼0.025), WT female progeny (p<0.0001) and Igf2þm/p, p53þ/ female progeny (p¼ 0.049, two-tailed t-test, NS¼ not significant).
708females (Igf2þm/p, p53þ/, Fig 2C and Supporting Information
Fig S3B and C).
Igf2Rm/p female specific lethality was associated with a
gene expression signature and lung haemorrhage
We next investigated effects of paternal genotype on gene
expression. Whole female embryos derived from WT, Igf2þm/p
or double heterozygote (Igf2þm/p, p53þ/) fathers were
obtained at E9.5 (Fig 3A). This time was chosen because it is
known that WT and Igf2þm/p embryos are of similar size at
E9.5, and we wished to eliminate confounding effects from later
differences in growth (Burns & Hassan, 2001). Illumina RNA
expression profiles of all female progeny at E9.5 were then
compared (Fig 3B). A specific gene expression signature was
observed in progeny that were derived from double hetero-
zygote fathers (Igf2þm/p, p53þ/; Fig 3B). Greater than two-fold
differences in gene expression were observed for 1461 genes
(Fig 3B lists the most differentially expressed genes) with the top 2012 EMBO Molecular Medicine50 differentially expressed genes further annotated (http://
www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1001; note
all microarray data and tables of genes described are available
from Arrayexpress). Importantly, no effects were consistent
with co-segregation of the gene expression signature with
the p53 null allele, suggesting the signature was a direct
consequence of the combined paternal genotype rather than a
segregating modifier allele. By filtering the initial signature of
1461 genes according to chromosomal location, we obtained 53
X-linked genes. These genes were distributed along the entire
length of the X-chromosome and failed to show any differential
expression patterns (data not shown).
We evaluated whether the gene lethality expression profiles
represented a hierarchy of transcriptional regulation. PScan
(Zambelli et al, 2009) determined transcription factors whose
binding sites were statistically over-represented in the 50 most
differentially expressed genes, including those located on the
X-chromosome. A single X-linked transcription factor, Zfx, wasEMBO Mol Med 4, 705–718 www.embomolmed.org
Research Article
Victoria L. Haley et al.
Table 2. Complete perinatal lethality of 129J Igf2þm/p female progeny was only observed from females mated with 129J Igf2þm/p, p53þ/ males.
Cross Time-
point







< , < , < , < , < , < ,
WT , x P0 74 82 54 59 – – – – – – – – 269
Igf2þm/p < (67) (67) (67) (67) p¼NS
0.67 3.23 2.61 1.01 7.54
P3.5 66 77 32 35 – – – – – – – – 210
(53) (53) (53) (53) p<0.0001
0.35 11.4 8.00 5.83 28.74
p53þ/ , x P10 20 18 13 18 16 22 13 17 – – – – 137
Igf2þm/p < (17) (17) (17) (17) (17) (17) (17) (17) p¼NS
0.48 0.04 0.99 0.04 0.99 1.39 0.07 0.00 4.02
WT , x E18.5 7 3 7 4 6 1 6 3 – – – – 37
Igf2þm/p, (5) (5) (5) (5) (5) (5) (5) (5) p¼NS
p53þ/ < 1.22 0.57 1.22 0.08 0.48 2.84 0.48 0.57 7.32
P0 9 9 5 0 8 8 9 2 50 p<0.05
(6.3) (6.3) (6.3) (6.3) (6.3) (6.3) (6.3) (6.3) 14.00
1.21 1.21 0.25 6.25 0.49 0.49 1.21 2.89
P10 6 12 4 0 6 13 6 5 – – – – 52
(6.5) (6.5) (6.5) (6.5) (6.5) (6.5) (6.5) (6.5) p<0.01
0.04 4.65 0.96 6.5 0.04 6.5 0.04 0.37 19.08
p53þ/ , x E9.5 6 7 4 4 10 15 9 11 2 3 4 5 80
Igf2þm/p, (5) (5) (5) (5) (10) (10) (10) (10) (5) (5) (5) (5) p¼NS
p53þ/ < 0.20 0.80 0.20 0.20 0.00 2.50 0.10 0.10 1.80 0.80 0.20 0.00 4.40
E18.5 3 2 1 3 5 7 5 4 3 2 2 3 40
(2.5) (2.5) (2.5) (2.5) (5) (5) (5) (5) (2.5) (2.5) (2.5) (2.5) p¼NS
0.10 0.10 0.90 0.10 0.00 0.80 0.00 0.20 0.10 0.10 0.10 0.10 1.40
P10 10 8 7 0 15 12 10 10 2 3 1 1 75
(4.7) (4.7) (4.7) (4.7) (9.4) (9.4) (9.4) (9.4) (4.7) (4.7) (4.7) (4.7) p¼NS y
6.02 2.34 1.14 4.7 3.38 0.74 0.04 0.04 1.54 0.61 2.90 2.90 12.487
Significant deviation from the normal expected Mendelian ratio of Igf2þm/p progeny from WT mothers at P3.5 in both females and males was detected,
suggesting an effect of the paternal allele on survival. The Igf2þm/p genotyped progeny derived from Igf2þ/, p53þ/ males were absent at P10 compared to
E18.5, although the significance was not detected in the segregation of genotypes in progeny derived from p53þ/ females (y).a regulator of the gene sets, although there were no differences
in Zfx mRNA levels (not shown; Cellot & Sauvageau, 2007;
Luoh et al, 1997). We also identified Igf2-dependent genes in
all females, with respect to the paternal genotype. A total of 41
Igf2-dependent genes, including Igf2 itself, were obtained
from this further analysis, with some apparent fold change
differences dependent on paternal p53þ/ status, suggesting
that Igf2 regulated genes may also be differentially modified
by p53. Using PScan (Zambelli et al, 2009) to locate putative
p53 binding sites in the promoters of the 50 most differentially
expressed genes between progeny that were derived from
double heterozygote fathers (Igf2þm/p, p53þ/) and controls,
we detected 48/50 potential p53 regulated genes. These
were located in autosomes, without overlap with Igf2 regulated
genes.
We next focused on the p53-dependent rescue of lethality in
Igf2þm/p females. We reasoned that genes responsible for
lethality would be differentially expressed in Igf2þm/p female
progeny of double heterozygote fathers (Igf2þm/p, p53þ/),
relative to the Igf2þm/p, p53þ/ female littermates that survive.www.embomolmed.org EMBO Mol Med 4, 705–718The expression levels of the lethality rescue genes would
be expected to be closer to those in Igf2þm/p embryos from
Igf2þm/p or WT fathers, i.e. that expression was normalized.
The genes identified as significantly different in Igf2þm/p
females compared to Igf2þm/p and Igf2þm/p, p53þ/ embryos
female littermates were then compared (Fig 3C). We obtained a
signature that most likely represented the gene changes
associated with p53þ/ rescue. The E9.5 ‘lethality (rescue)
signature’ (Fig 3C) contained 23 genes including those
encoding transcription factors (Zmiz2, Tbx6), endocrine
regulators (Sst), endocytosis (Necap2), metabolic enzymes
(Pck2, Man1a, Pus7) and the extracellular matrix protein,
fibronectin (Fn1).
We noted that the relative expression levels of Fn1 were high
compared to the other genes (Fig 3C). Previous work had
identified Fn1 gain of function as a modifier of lung branching
morphogenesis, associated with gain of cell–matrix adhesion
relative to the reciprocal repression of E-cadherin cell–cell
adherence (Sakai et al, 2003). Lung airspaces of the Igf2þm/p,
p53þ/þ females were filled with blood suggesting that 2012 EMBO Molecular Medicine 709
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Figure 3. Paternal p53 genotype alters embryonic gene expression and Igf2Rm/p female specific lethality.
A. Schema of embryonic RNA expression analysis. Three parental genotype pairs were crossed to yield a number of female embryos of specific genotype as
illustrated.
B. Comparison of gene expression in E9.5 female embryos derived from Igf2þm/p or WT fathers (WT and Igf2þm/p) with the expression in embryos from
Igf2þm/p, p53þ/ fathers (WT, Igf2þm/p, p53þ/ and Igf2þm/p, p53þ/). 1461 genes were significantly different in expression by SAM analysis and varied more
than twofold, with most differentially expressed genes displayed in the heatmap.
C. Comparison of gene expression in Igf2þm/p female embryos derived from WT fathers with those Igf2þm/p and Igf2þm/p, p53þ/embryos from Igf2þm/p,
p53þ/ fathers. ‘Rescue’ signature of 23 genes shown in the heatmap.
D. H & E-stained lungs from E19.5 Igf2þm/p female embryos (low power above, bar 1 mm, high power 100 mm) were filled with blood in both bronchioles (br)
alveolar air-spaces (alv) when compared to WT littermates. Confocal images showed there were no gross differences in lung structure labelled with E-cadherin,
but fibronectin was predominantly present in blood within the airspaces (white arrow), and subjectively increased in small airway and alveolar regions (white
arrow head). Bar¼100 mm.
710  2012 EMBO Molecular Medicine EMBO Mol Med 4, 705–718 www.embomolmed.org
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Victoria L. Haley et al.haemorrhage was the likely cause of death (Fig 3D). Laser
scanning confocal microscopy (LSCM) detected no obvious
gross structural alterations in vessels and airways, neither in
E-cadherin, Ki67 nor cleaved caspase-3 labelling (Fig 3D and not
shown). Localization of fibronectin showed increased labelling
in blood present in both large and small airways, presumably
related to its known role in coagulation. However, an increase
in fibronectin appeared in regions of the small airways and
alveoli in Igf2þm/p, p53þ/þ females compared to female and
male WT and Igf2þm/p, p53þ/ littermates (Fig 3D and not
shown).
Accelerated tumour formation in p53 heterozygote females
combined with loss of imprinting of Igf2 (H19m/Rp)
We next investigated dependencies of the p53 and Igf2 pathways
during tumour development. Neither allelic loss nor gain of Igf2
expression in WT (p53þ/þ) and homozygote null (p53/) mice
had any effect on tumour latency and overall longevity to
18 months, even though the IGF and p53 pathways were both
implicated in aging and longevity in the mouse (Donehower,
2002, 2009; Supporting Information Fig S4). Heterozygosity
of p53 (p53þ/) combined with bi-allelic expression of Igf2
(in this case associated with the 13 kb deletion of the H19 gene
and ICR H19D13kb), resulted in accelerated tumour formation in
B6, 129 or F2 backgrounds (Fig 4A–C). Interestingly, the effect
on tumour progression also appeared unusually specific to
females rather than males (Fig 4D). Control p53þ/ females and
males had similar tumour latencies (Fig 4D) indicating that the
acceleration in tumour formation in females was primarily due
to the consequences of D13 kb deletion on the Igf2-H19 locus.
The consequences of H19m/þp include the expected bi-allelicFigure 4. Bi-allelic Igf2 expression accelerates
tumour formation in p53R/ female mice,
irrespective of strain.
A. Survival of B6 H19m/þp, p53þ/ mice was sig-
nificantly reduced compared to p53þ/ mice
( p¼0.0065, log-rank test). Due to accelerated
tumour latency the humane end point was
brought forward to 400 days.
B. Survival of 129 H19m/þp, p53þ/ mice was
significantly reduced compared to Igf2þ/p,
p53þ/ ( p¼0.0001), Igf2þm/þp, p53þ/
( p¼0.008) and H19þm/þp, p53þ/ mice
( p¼0.036, log-rank test).
C. Survival of F2 hybrid H19m/þp, p53þ/ mice was
significantly reduced compared to Igf2þm/p,
p53þ/ ( p¼0.0008), Igf2þm/þp, p53þ/
( p¼0.0017) or H19þm/þp, p53þ/ mice
( p¼0.0018, log-rank test).
D. Tumour latency in B6 H19m/þp, p53þ/ female
mice was significantly reduced compared to
H19m/þp, p53þ/males and p53þ/ females and
male mice ( p<0.0007, log-rank test).
E. B6 H19m/þp, p53þ/mice had significantly more
solid tumours (carcinomas and sarcomas) and
fewer lymphomas than B6 H19þm/þp, p53þ/
mice ( p¼ 0.037, Fisher’s exact test).www.embomolmed.org EMBO Mol Med 4, 705–718expression of Igf2, loss of function of the H19 ncRNA and
associated miR-675, and the potential up-regulation of miR-483
in the Igf2 locus (Gabory et al, 2009).
A statistically significant alteration in tumour spectrum
occurred in p53þ/ mice with H19m/þp, with more tumours
classified as carcinoma and sarcoma compared to p53þ/ mice
(Fig 4E, Supporting Information Fig S5). Inactivation of the
remaining WT p53 allele by LOH is normally required for
tumour formation. We next determined the frequency of p53
LOH, mutation and the presence of p53 protein by IHC in
tumours and correlated this with latency and tumour spectrum
in H19m/þp, p53þ/ (Fig 5A; Supporting Information Table S4).
Overall, 70% (21/30) of tumours from p53þ/ littermates had
either LOH or mutation of p53 compared to 16.7% (2/12) of
tumours in H19m/þp, p53þ/ (Fig 5A). In carcinomas and
sarcomas, and to a lesser extent in lymphoma, p53 LOH
frequency appeared independent of loss of the paternal Igf2
allele (Fig 5B). In contrast, the untargeted (intact) p53 allele was
retained in sarcoma and carcinomas associated with bi-allelic
expression of Igf2 (Fig 5B), although this was independent of sex
(not shown). High Igf2 expression determined by quantitative
PCR was particularly associated with an intact p53 allele in
sarcomas that arose in H19m/þp, p53þ/mice, but was without
consistent differences in Mdm2 localization (Supporting
Information Figs S6 and S7). p53 LOH was detected with equal
frequency to intact alleles in all tumours with lower Igf2
expression (Fig 5C, Supporting Information Fig S7). For the
tumours that arose in H19m/þp, p53þ/, we detected 1/10 with
mutations in the p53 DNA-binding domain (Supporting
Information Table S4). Our data suggested that bi-allelic
expression of Igf2 and the associated disruption of the H19 2012 EMBO Molecular Medicine 711
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Figure 5. p53 mutation, LOH and apoptosis in
tumours from p53R/ mice with bi-allelic Igf2
expression (H19m/Rp).
A. Proportion of p53þ/ tumours with LOH/
mutation was significantly reduced in tumours
from mice bi-allelic for Igf2 (H19m/þp),
compared to mice null for Igf2þm/p and WT
(p<0.002, Fisher’s exact test).
B. 100% of sarcomas and carcinomas from
H19m/þp, p53þ/ retain an intact WT p53 allele
(n¼ 9), compared to 100% of LOH in the
littermate p53þ/ control mice (n¼5;
p¼ 0.0005, Fisher’s exact test)
C. Sarcomas with intact WT p53 (n¼6) had sig-
nificantly higher Igf2 mRNA expression than
lymphomas and carcinomas, irrespective of p53
allelic status ( p< 0.05–0.01, one-way
ANOVA, Tukey’s multiple comparison). Sample
annotation is as for genotypes in Fig 4A and B.
D. Solid tumours (n¼8) from H19m/þp, p53þ/
mice had significantly fewer apoptotic cells,
assessed by staining for cleaved caspase-3
(right) than solid tumours from H19þm/þp,
p53þ/ mice (n¼4, p¼<0.05, p¼< 0.01,
p< 0.001, one-way ANOVA, Tukey’s multiple
comparison). Blue, male; Red, female.
712locus may have reduced the selection pressure for inactivation
of the remaining WT allele of p53 mainly in carcinoma and
sarcoma.
To determine whether proliferation and apoptosis were
modified in the accelerated tumour formation from bi-allelic
H19m/þp, p53þ/ females, we performed immuno-labelling for
Ki67 proliferative marker and cleaved caspase-3 apoptotic
marker. In contrast to Ki67 labelling, cleaved caspase-3 labelling
was significantly reduced in solid tumours (carcinoma and
sarcoma) from p53þ/ mice when combined with bi-allelic Igf2
expression compared to tumours from mice with mono-allelic
Igf2 expression (Fig 5D). The correlation of cleaved caspase 3
labelling with Igf2 expression approached significance
(Supporting Information Fig S8). The cause of the sex-specific
acceleration of tumour development in females still remains
obscure. The effect may be either paternal or X-linked, as
oestrogen receptor (ER-a) immuno-labelling appeared indepen-
dent of sex, tumour histology or genotype (Supporting
Information Fig S9).
Igf2 dependency of the rapid tumour onset in p53 null using
combined conditional alleles
We next utilized a new conditional allele for Igf2 with loxp sites
that flanked either side of exons 4–6 (Sandovici et al, in
preparation), a conditional allele previously characterized for
p53, and combined these with a conditional tamoxifen inducible
Cre (ROSA26Cre; see Supporting Information Table S5). Igf2fl/fl,
p53fl/fl females were successfully bred with Igf2fl/þ, p53fl/þ,
R26CreERþ/ males on a C57BL6-FVBN background (Fig 6A).
Injection of tamoxifen (1 mg) to mothers at E10.5 generated
deletion alleles and the expected segregation of progeny
(37 males and 28 females, Supporting Information Fig S10A).
Non-quantitative PCR suggested that recombination was
incomplete as most tissues retained the loxp flanked allele
(Supporting Information Fig S10B). We were unable to either 2012 EMBO Molecular Medicineconditionally modify both alleles prior to embryonic day 8, or to
generate germ-line transmission of deleted alleles. Continued
breeding of males with p53 loxp flanked alleles resulted in
73 mice from 5.6 litters with normal transmission of non-
recombined alleles. Following recombination in utero, males
with deleted alleles (p53D/D or p53þ/D) generated only seven
progeny from 3 litters, with no subsequent transmission of the
deleted (recombined) p53 allele. By P30 the mean total body
weights (BW) and that of the eviscerated carcass of Igf2D/D,
p53D/D, R26CreERþ/ progeny was significantly less than that of
Igf2fl/fl, p53fl/fl littermates, indicating that at least in these tissues
Igf2-dependent functional growth effects could be detected
(Fig 6B). Compared to other organs, the growth findings imply
that Igf2-dependent total body and musculoskeletal growth may
extend beyond E10.5 (Burns & Hassan, 2001).
Tamoxifen treatment of homozygous conditional null Igf2D/D,
p53D/D mice with ROSA 26 driven Cre (R26CreERþ/), avoided
the combined lethality observed using germ-line transmission to
create Igf2m/p, p53/. Moreover, bi-allelic disruption of the
Igf2 allele eliminated the potential for tumour specific re-
expression of the imprinted Igf2 (silenced) maternal allele (LOI).
Mice with conditional deletion of both alleles of Igf2 and p53
developed a longer tumour latency (n¼ 14, three lymphomas,
four solid tumours, two unknown causes, no metastasis,
median survival¼ 325 days) compared to mice with conditional
deletion of p53 but retention of the paternal Igf2 allele (n¼ 19,
10 lymphomas, 1 solid tumour, 5 unknown causes, median
survival¼ 206 days, Fig 6C). Importantly, the time-dependent
onset of tumours mimicked that of the p53/ germ-line
modification (Supporting Information Fig S4). There was
a significant shift in tumour spectrum of Igf2Dm/þp, p53D/D,
R26þ/ mice relative to Igf2D/D, p53D/D, R26þ/ mice with aEMBO Mol Med 4, 705–718 www.embomolmed.org
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Figure 6. Decreased tumour latency and altered tumour spectrum following homozygous conditional deletion of both Igf2 and p53.
A. Progeny from the homozygous conditional cross of Igf2fl/fl, p53fl/fl females Igf2fl/fl, p53fl/fl, R26þ/ males segregated according to the expected Mendelian
distribution at P10, regardless of sex.
B. Following maternal IP injection of tamoxifen at E10.5, BW and musculoskeletal weights (MS) of carcasses, were significantly less for Igf2D/D, p53D/D, R26Creþ/
mice (n¼ 6) compared to sham injected controls Igf2fl/fl, p53fl/fl, R26Creþ/ (n¼ 3, p¼0.05, unpaired t-test). No significant differences in the weight of viscera
were detected; Br, brain, Int, small intestine; Liv, liver; Lu, lungs; Kid, kidney; Hrt, heart; Thy, thymus. Plot shows 95% of the range (whiskers), interquartile range
(box), median (horizontal crossbar) and mean (cross).
C. Mice with homozygous conditional deletion of Igf2 and p53 (Igf2D/D, p53D/D, R26þ/) developed tumours later and survived for longer (median survival¼ 325 days)
than mice with an intact paternal allele of Igf2 (Igf2Dm/þp, p53D/D, R26þ/, median survival¼206 days, p¼ 0.024, log-rank test, blue, males; red, females).
D. Igf2D/D, p53D/D, R26þ/ mice (right) developed more solid tumours than Igf2Dm/þp, p53D/D, R26þ/ mice (left, 4 and 1, respectively), and fewer lymphomas
(3 and 10, respectively, p¼0.0474, Fisher’s exact test).reduction in lymphoma development relative to carcinoma and
sarcoma (Fig 6D). These results confirm that allelic dose of Igf2
significantly reduced the onset of homozygote p53 null tumour
phenotype for all types of tumours.DISCUSSION
Single cell type in vitro models tend to lack tissue specific auto-
regulatory feedback loops, and so, although informative,
significance for in vivo function may be limited (Feng & Levine,
2010). Here, we exploited the imprinting regulation of Igf2, a
developmental and tumour growth factor, to both increase and
decrease the allelic dosage of Igf2 and ligand supply. An
assumption was that genetic modifications altered Igf2 expres-
sion alone. As in most mouse models, disruption of genomic
regions can generate direct and indirect effects, with altered
expression of microRNAs as an example. Loss of miR-675 in the
H19ncRNA can promote tumour formation, as can an increase in
miR-483 within the Igf2 region (Gabory et al, 2009; Veronese
et al, 2010; Yoshimizu et al, 2008). A second assumption is thatwww.embomolmed.org EMBO Mol Med 4, 705–718alteration of IGF2 ligand supply leads to physiological activation
of the pathway. The proportionate growth effects of the Igf2
models support this assumption when compared to un-
physiological expression derived from introduced transgenes.
The resulting increase in supply of IGF2 would bind cell surface
IGF1R and IR-A, to activate downstream signalling to all intact
pathway components, and specific feedback mechanisms
(Ulanet et al, 2010).
Igf2-dependent developmental lethality and an Igf2-
dependent modification of tumour formation occurred in p53
null mice. When Igf2þm/p has been previously combined with
genetic models of tumour susceptibility, including several
developmental genes, there has been little evidence for
combined lethality with this allele, suggesting that the
synergistic lethality phenotype we now describe with p53
is novel (Christofori et al, 1994; Hassan & Howell, 2000;
Ho et al, 2009; Wu et al, 2006). Thus, our observation
that homozygote null p53 mice fail to survive to adulthood in
the context of disruption of the paternal allele of Igf2 suggests
Igf2 is required to rescue a p53 loss of function-dependent
lethality. 2012 EMBO Molecular Medicine 713
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714The specific lethality in Igf2þm/p female progeny was
genetically attributed to double heterozygote fathers. The
paternal X-chromosome appears a prerequisite for lethality of
the Igf2þm/p females because of the survival of male Igf2þm/p
progeny. Female Igf2þm/p, p53þ/ progeny also survived,
albeit at lower than expected numbers, indicating that loss of
one allele of p53 from the genotype of the offspring was
sufficient for a partial rescue of the female specific lethality. We
speculate that potential rescue mechanisms might include
interactions of p53 with a range of epigenetic and X-specific
targets, e.g. DNA methyltransferases (Dnmt; Park et al, 2005;
Peterson et al, 2003) and Xist expression (Panning & Jaenisch,
1996). In Igf2m/p mice, the canalicular phase of lung
maturation during late gestation appeared delayed, leading to
lungs having poorly organized alveoli with thick septae and
reduced airspaces (Silva et al, 2006). Reduced exposure to
maternal corticosteroids may have been responsible for the
delayed lung development since progeny from Igf2m/p
mothers treated with this glucocorticoid had lung architecture
similar to that of WT controls (Silva et al, 2006). None of these
effects were sex or female specific as in our case. Fibronectin
(Fn1) is the major component of the extracellular matrix in the
lung and excess supply promotes epithelial branching morpho-
genesis (Sakai et al, 2003). The ten-fold increase in expression of
Fn1 in Igf2þm/p, p53þ/þ female genotyped embryos destined to
die, with lower levels in surviving Igf2þm/p, p53þ/ littermates,
appeared significant, yet we could not reliably infer the
phenotype was Fn1 dependent. Expression of Man1a2 gene,
which encodes golgi a1,2-mannosidase IB, was also elevated in
Igf2þm/p, p53þ/þ female progeny. Homozygous knock-out of
Man1a2 produced a surprisingly severe lung phenotype that
resulted in neonatal lethality (Tremblay et al, 2007). Impor-
tantly, Man1a2/ mice died hours after birth from respiratory
distress and alveolar haemorrhage, mirroring our phenotype
even though in our case Man1a2 appeared up-regulated
(Tremblay et al, 2007).
Deletion of the H19 locus (Leighton et al, 1995) is an imperfect
model of LOI for Igf2. Importantly, we cannot exclude the
possibility that some of the effects that we observe may be due to
removal of H19 non-coding RNA, as been demonstrated in the
small intestine (Yoshimizu et al, 2008). H19 long non-coding
RNA has putative roles as a tumour suppressor (Yoshimizu et al,
2008) and regulator of embryonic growth (Gabory et al, 2009),
mainly through loss of microRNA, miR-675, which is hosted by
H19 within its first exon (Cai & Cullen, 2007; Mineno et al,
2006). Thus the consequences of the 13 kb deletion in the
H19m/þp model we utilized may also have had Igf2-indepen-
dent gain of function effects on the p53 pathway. However, our
previous analysis of miRNA profiles from these Igf2 models
revealed numerous other miRNA changes, despite Igf2 specific
phenotypic effects in the context of Pten heterozygosity (Church
et al, 2011).
The tumour-promoting effect of H19m/þp appeared inde-
pendent of the direct loss of the WT p53 allele (LOH) in
carcinoma and sarcoma tumours. We cannot however explain
the female dependency of this phenotype, except to propose that
it may depend on either the X chromosome, a strain modifier or 2012 EMBO Molecular Medicinevia early hormonal changes (Harvey et al, 1993; Jacks et al,
1994). It has been observed that anti-tumour effects can occur
following re-introduction of a WT p53 allele in p53 null tumours
(Martins et al, 2006; Ventura et al, 2007; Xue et al, 2007). Our
data suggest that counteracting the inhibitory effects of the IGF2
pathway on the endogenous WT p53 allele, may also lead to re-
activation of the endogenous WT p53 allele, and promote
tumour suppression. In tumours with intact p53 alleles and Igf2
over-expression, inhibiting the IGF2 signalling pathway may
offer a therapeutic strategy. Conditional homozygous deletion of
both Igf2 and p53 alleles slowed the development of tumours
compared with the conditional deletion of p53 alleles alone.
Thus, p53 loss of function in both development and tumour
formation appears dependent on Igf2. The Igf2 dependency of
tumours that arise in the context of other models associated with
p53 loss of function implicates Igf2 as a significant factor that
regulates the progression of tumours through regulation of
apoptosis (Christofori et al, 1994, 1995; Lopez & Hanahan,
2002), more recently observed in a mouse model of high grade
chondrosarcoma (Ho et al, 2009). In the chondrosarcoma
model, a p53-dependent reduction of IGFBP levels may have
accounted for a secondary increase in IGF2 ligand bio-
availability, and hence dependence on Igf2. The dependency
of tumour growth on the IGF pathway is further supported by
observations in Li-Fraumeni associated tumours, as adrenal
carcinoma and osteosarcoma have both been associated with
dependency on IGF2, and are the basis of interventional clinical
trials of agents that inhibit the activation of the IGF1 receptor
(Avnet et al, 2009; Barlaskar et al, 2009). These data suggest that
regulation of the IGF2 ligand in tumour susceptibility syndromes
associated with p53 (e.g. Li-Fraumeni, p53 and MDM2
associated SNPs) may be a potential strategy for tumour
prevention. Finally, we cannot extend these observations to
either gain of function mutants of p53, where partial, complete
and altered pathway interactions may be evident (Hinkal et al,
2009). These issues require further genetic investigation during
development and tumour formation.MATERIALS AND METHODS
Animals and genotyping
Animal work was approved by University of Oxford ethics committee
and UK Home Office. Mice [Mus musculus C57BL/6J (B6) and 129S2/J
(129)] were maintained and genotyped as previously described
(Hassan & Howell, 2000; Supporting Information Table S5, primers
available on request). The new Igf2 conditional allele has loxp sites
flanking exons 4–6 and was maintained (>10 generations) on a
C57Bl6 background (Sandovici et al in preparation). Seminal plugs at
9.00 am and conception was taken 12h. Weighed embryos were
fixed in either 4% neutral buffered formalin (NBF) or RNAlater (Qiagen,
Crawley, UK). DNA from E9.5 embryo yolk sacs was extracted by TRI
reagent (Applied Biosystems, Warrington, UK). To distinguish Igf2þm/p
from Igf2m/þp, embryos with reduced CR length and low Igf2
expression with qPCR were designated as being Igf2þm/p. Recombi-
nation of conditional alleles by R26CreERþ/ was with Tamoxifen
(1mg, 5% v/v ethanol and 95%v/v corn-oil, Sigma, Poole, UK) injectedEMBO Mol Med 4, 705–718 www.embomolmed.org
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The paper explained
PROBLEM:
The p53 gene product is a transcription factor that controls the
cells’ response to genome toxins, such as radiation, and is a
frequently mutated target in cancer. Inherited mutation of
the p53 gene can predispose humans to early onset cancers
(Li-Fraumeni syndrome, LFS), and this effect can be reproduced in
the mouse. When tumours form, the remaining wild-type (WT)
allele is lost either through loss of genomic DNA in a process
called ‘loss of heterozygosity (LOH)’, or by inhibition of p53. The
pathways that modify the age of onset of LFS cancers are
potential targets for screening and therapy, and such pathways
may also be potential targets to restore function when p53
function is lost. Molecular interactions between p53 and a
growth signalling pathway regulated by insulin-like growth
factor (IGF) ligands have been observed in cell culture models. To
date there has been no systematic analysis of the consequences
of gain and loss of supply of the IGF2 ligand in the context of loss
of p53 function in the whole organism.
RESULTS:
We addressed the problem by taking a comprehensive genetic
approach in the mouse. We combined mice that lack supply of
the IGF2 ligand (Igf2 null) and mice with increased supply of Igf2
(bi-allelic expressed alleles) with mice that were p53 hetero-
zygote and homozygote. If both these genes were homozygote
null in all tissues, then embryonic development failed, suggesting
an important pathway interaction. Interestingly, if the breeding
male was heterozygote for both genes, only females with loss of
the male derived Igf2 allele developed a haemorrhagic lung
syndrome, suggesting a more specific interaction. Importantly,
the age of tumour onset was either reduced or increased if
the supply of IGF2 was decreased and increased, respectively.
When IGF2 supply was increased, we also observed that the
WT p53 allele remained intact in an altered tumour spectrum
towards carcinoma and sarcoma, suggesting the mechanism
of suppression of p53 was independent of LOH in these
tumours. Targeting IGF2 supply in this instance may
reactivate the suppressed p53 and generate anti-tumour
mechanisms.
IMPACT:
Screening patients with LFS can be a very effective method to
detect early tumour formation and prevent development of
lethal cancers. For some sporadic cancers, such as bone and soft
tissue sarcoma that are frequently observed in LFS, defects in the
p53 pathway have also been observed, suggesting that the
sporadic development of p53-dependent cancers may in fact
represent a spectrum of susceptibility ranging from germ-line
mutation to pathway polymorphisms. To date, no therapeutic
agents have been developed that modify the age of onset either
in LFS tumours or in tumours (sarcoma) that arise in the context
of p53 pathway modification rather than inherited gene
mutation. Interruption of the IGF2 signaling pathway, for
example by specific targeting of the ligand, may therefore be a
useful mechanism to test the prevention of human tumours with
a disrupted p53 pathway. Moreover, targeting IGF2 may be a
treatment strategy in selected patients with tumours that arise
in the context of p53 pathway disruption without LOH but with
increased IGF2 pathway activity.I.P. at E10.5. Humane end-point for tumour burden was set at 18
months. Animals were checked daily for palpable tumours and
evidence of systemic decline (weight loss, lack of grooming, reduced
activity and piloerection).
RNA extraction, reverse transcription and qPCR
Material stored at 808C in RNAlater (Applied Biosystems) were
homogenized with either an Ultra-Turrax T8 (Ika Labortechnik,
Staufen, Germany) or by a 25-gauge needle. A total nucleic acid
isolation kit (Applied Biosystems) was used to extract RNA from
formalin-fixed paraffin embedded (FFPE) tissue. RNA was quantified
by NanoDrop 1000 (Thermo Fisher Scientific, Loughborough, UK).
RT-PCR (High-Capacity cDNA Reverse Transcription Kit, Applied
Biosystems) prior to quantitative PCR normalized to the expression
of b-actin (primer sequences available on request).
Immunohistochemistry and microscopy
Paraffin-embedded tissues were sectioned and stained with haema-
toxylin and eosin (H & E; Hassan & Howell, 2000). Antibodies and
antigen retrieval methods are available on request. Sections were
blocked (1 h, 1.5%v/v) with goat or rabbit serum, or overnight using awww.embomolmed.org EMBO Mol Med 4, 705–718Mouse-on-Mouse kit (Vector Laboratories, Peterborough, UK), and
incubated with primary antibody either at 48C (overnight) or at room
temperature (RT, 1 h). Secondary labelling was with either biotinylated
(Vectastain elite avidin–biotin complex kit, Vector Laboratories) or
alexa-fluor 594-conjugated secondary antibodies and counterstained
with haematoxylin or 40 ,6-diamidino-2-phenylindole (DAPI; Invitro-
gen). Digital images were acquired using a Zeiss LSM 510 confocal
microscope (Carl Zeiss, Welwyn Garden City, UK) and a Nuance MSI
camera (CRi, Woburn, MA) and analysed using Nuance 2.4.10
software. The percentage of Ki67 or cleaved-caspase 3 positive cells
was scored by counting at least 500–1000 cells from 4 to 5 fields per
tumour.
Microarray gene expression profiling and bioinformatics
RNA from E9.5 embryos were hybridized to Illumina Mouse Whole
Genome 6 v1.1 or v2 BeadChips (Illumina, San Diego, CA) by
Cambridge Genomic Services (Cambridge, UK) or Wellcome Trust
Centre for Human Genetics (Oxford, UK). Bioinformatics included R
2.12.0, (R Development Core Team, 2010) with microarray-specific
packages obtained from the Bioconductor repository (Bioconductor
2.7, (Gentleman et al, 2004). Raw data were normalized with ‘lumi’ 2012 EMBO Molecular Medicine 715
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716(Du et al, 2008) and Significance Analysis of Microarrays (Tusher et al,
2001) with ‘siggenes’. Mapping of Illumina identifiers to annotation
terms was done with ‘biomaRt’ and data from the Ensembl BioMart
database (European Bioinformatics Institute, Cambridge, UK).
LOH and mutation analysis
PCR for p53 LOH with primers are described in Supporting Information
Table S5. PCR products were purified with a Zymoclean Gel DNA
Recovery Kit (Cambridge Bioscience, Cambridge, UK) and sequenced by
GeneService (Oxford, UK).Author contributions
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